Application No 9/187,693
Response dated October 3, 2003
In Response to August 27, 2002 final Office Action

## Amendments to the Claims

Please amend claims 1-4, 6, and 7 as follows. This listing of claims will replace all prior versions, and listings, of claims in the application.

## Listing of Claims

1. (Currently Amended) An <u>isolated human</u> antibody that binds to <u>human</u> epidermal growth factor receptor (EGF-r), that wherein said antibody is characterized by the following functions:

Inhibits tyrosine phosphorylation of EGF-r;
Is internalized with EGF-r;
Inhibits the degradation of EGF-r; and
Inhibits the EGF induced degradation of EGF-r.

- 2. (Currently Amended) An <u>isolated human</u> antibody that binds to <u>human</u> epidermal growth factor receptor, that wherein said antibody is characterized by the following functions: Protects protects threonine phosphorylation of EGF-r.
- 3. (Currently Amended) An <u>isolated human</u> antibody that binds to <u>human</u> epidermal growth factor receptor, that wherein said antibody is characterized by the following functions: Protects protects threonine phosphorylation of a 63 KD protein.
- 4. (Currently Amended) An <u>isolated human</u> antibody that binds to <u>human</u> epidermal growth factor receptor,

Application N 09/187,693 Response dated October 3, 2003 In Response to August 27, 2002 final Office Action

that wherein said antibody is characterized by the following functions:

Inhibits VEGF production by tumor cells by greater than 50%; and Inhibits VEGF production by endothelial cells by greater than 40%.

- 5. (Original) The antibody of Claim 4, wherein the tumor cells are A431 cells.
- 6. (Currently Amended) The antibody of Claim 4, wherein the tumor endothelial cells are ECV304 cells.
- 7. (Currently Amended) An <u>isolated human</u> antibody that binds to <u>human</u> epidermal growth factor receptor, that wherein said antibody is characterized by the following functions:

Inhibits tyrosine phosphorylation of EGF-r;
Is internalized with EGF-r;
Inhibits the degradation of EGF-r;
Inhibits the EGF induced degradation of EGF-r;
Protects threonine phosporylation phosphorylation of EGF-r;

Protects threonine phosphorylation of a 63 KD protein;

Inhibits VEGF production by tumor cells by greater than 50%; and

Inhibits VEGF production by endothelial cells by greater than 40%.